Results 101 to 110 of about 15,738 (210)
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Eosinophilic esophagitis (EoE) is a chronic, immune‐mediated disease requiring long‐term therapy. Dupilumab, an interleukin‐4 and interleukin‐13 receptor antagonist, is approved for EoE at a weekly 300 mg dosing regimen. However, data on reduced‐frequency dosing, especially in pediatric patients, remain limited.
Giovanni Scatigna +4 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Introduction Traditional fish smoking in Abuesi, Ghana, exposes workers, primarily women, to significant health risks due to prolonged smoke inhalation. This study evaluates the knowledge, attitudes, and practices (KAP) concerning safe smoking methods.
Frank Adusei‐Mensah +8 more
wiley +1 more source
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo +14 more
wiley +1 more source
Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.Short‐term topical ocular steroids and NSAIDs did not result in statistically significant gastrointestinal bleeding or histopathological injury in healthy rats. Limited faecal occult blood positivity was observed in some steroid‐treated animals but was not accompanied by macroscopic or microscopic evidence of mucosal damage .
Harun Cinar +4 more
wiley +1 more source
Veterinary Record Case Reports, Volume 14, Issue 2, May 2026.Abstract This case report describes two dogs exhibiting severe behavioural problems, both diagnosed with early‐life giardiasis and raised in environments lacking adequate maternal care and socialisation. Both dogs experienced chronic gastrointestinal and dermatological issues, as well as prolonged early‐life stress, which likely contributed to ...
Daniëlle Hartman +3 more
wiley +1 more source
Clinical and computed tomographic characteristics of conjunctival large cell lymphoma in a cat
Veterinary Record Case Reports, Volume 14, Issue 2, May 2026.Abstract This case report describes a 12‐year‐old, female, neutered domestic shorthair cat presenting with an acute, diffuse, non‐resolving mass‐like lesion affecting the right conjunctiva. Despite an initial conscious snip biopsy result negative for malignancy and contrast‐enhanced computed tomography findings suggestive of sino‐orbital aspergillosis,
Yuet Yee Pang +2 more
wiley +1 more source
Chinese Position Paper on Biologic Therapy for Allergic Rhinitis
Allergy, Volume 81, Issue 5, Page 1354-1369, May 2026.ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang +37 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT The approval of baricitinib and ritlecitinib for alopecia areata (AA) marks the beginning of the Janus kinase (JAK) inhibitor era in AA treatment. Tofacitinib, a first‐generation JAK1/3 inhibitor, has theoretical potential to treat AA; however, real‐world evidence, particularly on comparative outcomes across patient subgroups and patient ...
Yifan Jin +7 more
wiley +1 more source
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin +24 more
wiley +1 more source